03320 CHINARES PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 1.42X | Oper Margin | 5.0% |
|---|---|---|---|
| LT Debt/Equity | 42.9% | Net Margin | 1.5% |
| Total Debt/Equity | 140.8% | Return on Equity | 7.9% |
| Price/Book | 0.69X | Return on Assets | 1.4% |
| (HKD 6.270) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 4,499.27 | 3,542.81 | 4,248.15 | 3,924.50 | 3,768.89 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +27.0 | -16.6 | +8.3 | +4.1 | +14.3 |
| Earnings Per Share (HKD) | 0.716 | 0.564 | 0.676 | 0.625 | 0.6 |
| Earnings Per Share Growth (%) | +27.0 | -16.6 | +8.2 | +16.8 | +14.3 |
| Dividend Per Share (HKD) | 0.215 | 0.146 | 0.170 | 0.160 | 0.150 |
| P/E* (X) | 8.75 | 11.12 | 9.27 | 10.04 | 10.45 |
| Yield (%) | 3.42 | 2.33 | 2.71 | 2.55 | 2.39 |
| Dividend Share (%) | 29.98 | 25.91 | 25.10 | 25.61 | 25.00 |
| Book NAV (HKD) | 9.108 | 8.167 | 8.063 | 7.773 | 8.115 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 269,574 | 257,673 | +4.6 | 244,704 |
| Operating Result | 11,491 | 10,492 | +9.5 | 9,399 |
| Associates | 261.964 | 368.014 | -28.8 | 417.106 |
| Profit Before Taxation | 11,796 | 10,930 | +7.9 | 9,880 |
| Taxation | 2,143 | 2,527 | -15.2 | 2,105 |
| Profit /( Loss) After Taxation | 9,653 | 8,403 | +14.9 | 7,775 |
| Minority Interests | 5,608 | 5,052 | +11.0 | 3,921 |
| Net Profit | 4,042 | 3,331 | +21.3 | 3,854 |
| Earnings Per Share () | 0.7162 | 0.5639 | +27.0 | 0.6762 |
| Dividend Per Share () | 0.2147 | 0.1461 | +47.0 | 0.1697 |
| Announcement Date | 2026-03-25 | 2025-03-26 | NA | 2024-03-26 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
